Daniel Martins-de-Souza

Life Sciences

Biologist Daniel Martins-de-Souza is on a mission to understand mental illnesses at a molecular level. He has initiated a project to analyze brain tissue and blood samples from patients with schizophrenia. Using mass spectrometry, Daniel can pinpoint specific peptides in a patient’s blood. These biomarkers could enable doctors to predict a drug’s effectiveness for a particular patient more accurately. His research forms the foundation for the development of personalized medicine.

Daniel holds a professorship at the Institute of Biology at UNICAMP, where he also earned his PhD in functional and molecular biology. He has worked in the Department of Psychiatry at Ludwig Maximilians University in Germany and was the head of the CCNR Mass Spectrometry group at Cambridge University in England.


Harnessing Predictive Biomarkers and Unveiling Biological Mechanisms to Revolutionize Schizophrenia Treatment
Science / Life Sciences

This project is focused on examining proteins and lipids in blood plasma obtained from schizophrenia patients. The goal is to uncover biomarkers, which have been elusive until now, that can predict the effectiveness of specific medications. The biochemical pathways implicated in the onset and progression of schizophrenia will also be studied in human brain tissue and pre-clinical models. A deeper understanding of the disorder’s molecular underpinnings could pave the way for developing a targeted therapeutic strategy.

Amount invested

R$ 100,000.00

Open Calls

Science Call 1
  • Topics
  • Antipsychotics
  • Biomarkers
  • Personalized medicine
  • Schizophrenia